Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
CSL
Biotech
Lilly pays CSL $100M for IL-6 drug that flunked transplant study
Lilly is paying $100 million for the right to develop a phase 3-stage IL-6 antibody that had previously been explored for organ transplant rejection.
James Waldron
Feb 18, 2026 5:07am
Sanofi's stunning CEO switch—Chutes & Ladders
Feb 13, 2026 8:30am
CSL inks $328M Memo deal for option on antibody engineering tech
Feb 9, 2026 2:00am
CSL pays $117M for option on phase 3 blood clotting specialist
Sep 16, 2025 4:31am
CSL to lose up to 15% of staff, cut R&D costs, spin out vaccines
Aug 19, 2025 7:06am
CSL consolidates R&D team in shift toward external partners
Jul 7, 2025 12:44pm
